BridgeBio Pharma BBIO EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's EBITDA?
- BridgeBio Pharma (BBIO) reported EBITDA of -$104.77M in Q1 2026.
- How has BridgeBio Pharma's EBITDA changed year-over-year?
- BridgeBio Pharma's EBITDA decreased by 1.6% year-over-year, from -$103.09M to -$104.77M.
- What is the long-term trend for BridgeBio Pharma's EBITDA?
- Over 4 years (2021 to 2025), BridgeBio Pharma's EBITDA has grown at a -2.4% compound annual growth rate (CAGR), from -$570.79M to -$517.98M.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.